Febuxostat 40 mg daily appears to be as efficacious as allopurinol in lowering serum uric acid levels. [38] Both febuxostat 40 and 80 mg can be given to patients with mild-to-moderate renal impairment ...

Learn everything you need to know about Febuxostat-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

Hyperuricemia is frequently observed among patient with chronic kidney disease. Febuxostat may offer superior renal-protective effects compared with allopurinol in patients with stage 3 chronic kidney ...

(UPDATED) Despite worries over a potential CV risk with febuxostat, there is indeed a population of patients with gout for whom the risk-benefit profile is favorable for the treatment of hyperuricemia ...

Febuxostat is a generic oral tablet prescribed for gout in some adults. It’s available as the brand-name drug Uloric. The cost of febuxostat with and without insurance can depend on several factors.

Response to febuxostat differed based on hyperuricemia subtype in older patients with gout, with the combined subtype linked to the lowest rates of SU target achievement.

The comparative efficacy of these therapies has been extended to patients with stage 3 chronic kidney disease, a common comorbidity in gout. Allopurinol and febuxostat are similarly effective in ...

Febuxostat is a xanthine oxidase (XO) inhibitor, prescribed for gout and hyperuricemia (high level of uric acid in blood). The serum concentration of the active metabolites of Ambroxol acefyllinate ...

Febuxostat is a novel, non-purine, selective inhibitor of xanthine oxidase for hyperuricemia in patients with gout. It is the first promising substitute for allopurinol in 40 years. Various synthetic ...

Hyperuricemia in patients with gout is most commonly treated with allopurinol. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, could potentially be a therapeutic alternative for ...

The efficacy and safety of febuxostat was noninferior to allopurinol for preventing tumor lysis syndrome (TLS) in patients with malignant tumors about to receive chemotherapy, according to a new study ...

Am J Health Syst Pharm. 2011;68(5):389-398. As a xanthine oxidase inhibitor, febuxostat may interact with drugs that are metabolized by xanthine oxidase. Febuxostat is currently contraindicated in ...